Anemia is mostly associated with chronic kidney disease (CKD) patients.
Anemia in CKD patients occurs due to the lack of erythropoietin. Low
hemoglobin concentration relates to bad clinic outcome toward CKD patients.
Epoetin therapy for CKD patients has been clinically confirmed to improve the
quality of life and lower the morbidity and mortality rate. This research was
intended to investigate the anemia profile therapy, adjuvant per-oral anemia
therapy adherence profile and the effect of adjuvant per-oral anemia therapy
adherence toward achievement target of anemia therapy using epoetin in CKD
Askes patient receiving regular haemodialysis therapy at PKU Muhammadiyah
Hospital Yogyakarta.
The research was conducted using observational study design with
prospective data collection, then the data were analyzed in order to know
the success of anemia primary therapy via epoetin and adjuvant per-oral anemia
therapy. The success of therapy were measured based on National Kidney
Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI), 2006,
while adherence was measured via Modified Morisky Scale (MMS) questionaire.
Based on the research, epoetin used in this research was epoetin alpha and
beta, each 69.05% and 30.95%. Adjuvant per-oral anemia therapy used in this
research was combined folic acid, iron and vitamin B-complex (82.05%